Researchers have found that in addition to CD4s, macrophage cells can harbor HIV even in the face of antiretroviral treatment.
April 28, 2017
____________________________________________________________________________________
____________________________________________________________________________________
In yet another finding that complicates HIV cure science, researchers
have established that in addition to CD4s, macrophage immune cells can
harbor virus in the face of antiretroviral (ARV) treatment and prompt a
viral rebound if treatment is interrupted. The findings of their
research, which was conducted in humanized mice, means that not one but
two types of immune cells likely make up the viral reservoir, the
existence of which prevents standard ARV treatment from curing the
virus.
Publishing their findings in Nature Medicine,
researchers built on laboratory research finding that macrophage immune
cells could support HIV replication in the absence of CD4 cells. They
conducted experiments on mice that were genetically engineered to have
human immune systems that lack CD4s.
They found that
ARV treatment strongly suppressed HIV replication in macrophage cells of
the infected mice. After stopping treatment in the animals, the virus
rebounded in a third of them.
The research team will
now investigate what regulates the persistence of the virus in
macrophage cells, where these persistently infected cells hide out in
the body during ARV treatment and how macrophages respond to treatments
that seek to eradicate the virus from the body.
To read a press release about the study, click here.
To read the study abstract, click here.
Read more articles from POZ, here.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.